Wellington Management Group
AXSM icon

Wellington Management Group’s Axsome Therapeutics AXSM Stock Holding History

Wellington Management Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160M Sell
653,920
-491,386
-43% -$107M 0.03% 434
2026
Q1 		$194M Sell
1,145,306
-76,350
-6% -$13.2M 0.04% 388
2025
Q4 		$223M Sell
1,221,656
-112,904
-8% -$15.8M 0.04% 360
2025
Q3 		$162M Buy
1,334,560
+609,516
+84% +$68.7M 0.03% 434
2025
Q2 		$75.7M Buy
725,044
+21,765
+3% +$2.3M 0.01% 597
2025
Q1 		$82M Buy
703,279
+30,122
+4% +$3.43M 0.02% 558
2024
Q4 		$57M Sell
673,157
-69,588
-9% -$6.4M 0.01% 674
2024
Q3 		$66.8M Buy
742,745
+8,125
+1% +$709K 0.01% 637
2024
Q2 		$59.1M Buy
734,620
+57,974
+9% +$4.29M 0.01% 661
2024
Q1 		$54M Buy
676,646
+436,827
+182% +$36.7M 0.01% 689
2023
Q4 		$19.1M Buy
239,819
+2,265
+1% +$151K ﹤0.01% 951
2023
Q3 		$16.6M Buy
237,554
+37,843
+19% +$2.83M ﹤0.01% 974
2023
Q2 		$14.4M Buy
+199,711
New +$14.7M ﹤0.01% 1022

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wellington Management Group's AXSM Position: Q2 2026 in Review

Wellington Management Group reduced its Axsome Therapeutics (AXSM) stake by 43% in Q2 2026, selling an estimated $107M and leaving 653,920 shares worth $160M. The position accounts for 0.03% of the portfolio, ranked #434.

Wellington Management Group first reported a position in AXSM in Q2 2023 and has held it in 13 quarters since. The position peaked at $223M in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Wellington Management Group held 653,920 shares of Axsome Therapeutics worth $160M as of Q2 2026.
  • Wellington Management Group sold 491,386 Axsome Therapeutics shares in Q2 2026, an estimated $107M.
  • Axsome Therapeutics made up 0.03% of Wellington Management Group's portfolio in Q2 2026, its #434 holding.
  • Wellington Management Group first reported a position in Axsome Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • Wellington Management Group's Axsome Therapeutics position peaked at $223M in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.